BioIntelliSense, a Colorado-based remote patient monitoring company, has raised USD 45 million in an oversubscribed Series B funding round, led by Chimera (UAE), with participation from existing and new investors.

The funding will be directed towards scaling its digital health and clinical intelligence platform as well as to globally expand its wearable devices and data services for remote patient care.

Founded in 2018, BioIntelliSense offers a Data-as-a-Service (DaaS) platform and FDA-cleared medical device ‘BioSticker’, which the company claims is an industry-first multi-parameter wearable device for remote patient monitoring. The company has also introduced the health screening tool ‘BioButton’, a disposable wearable device that monitors vital signs such as temperature, heart rate, and respiratory rate, used in the Covid-19 pandemic for remote patient care.